Roche Holding stock: Jefferies lifts target for Roche Holding stock to CHF 250.00

Published on 10/16/2026 at 17:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Roche schedules third-quarter sales for October 22, 2026. Roche Holding stock costs EUR 408.88 on October 16, 2026 at Lang & Schwarz after hours.

Analyst view and trading date

Jefferies set a CHF 250.00 target for Roche on October 9, 2026.
Roche will publish third-quarter sales on October 22, 2026.
Roche Holding stock costs EUR 408.88 at Lang & Schwarz on October 16, 2026 at 5:41 p.m. CEST after hours.
Roche trades at a price-to-earnings ratio of 24.69.

Automatisches Diagnostik-Laborgerät mit Touchscreen-Oberfläche im klinischen Labor — Roche Holding AG CH0012032048 – Diagnostik-Analysegerät verarbeitet biologische Proben im modernen klinischen Labor, Illustration mit AI erstellt.

Jefferies raised its Roche target from CHF 230.00 to CHF 250.00 on October 9, 2026, while retaining an Underperform rating, according to FinanzNachrichten.de. The target sits 35.00 percent below Roche's CHF 384.60 last price on the Swiss listing. Roche Holding was at EUR 408.88 at Lang & Schwarz on October 16, 2026 at 5:41 p.m. CEST after the Xetra close.

Target remains below the Swiss price

The Jefferies change gives investors a quantified view of the valuation debate. Its CHF 250.00 target is 35.00 percent below the CHF 384.60 last price reported for the Swiss listing on October 16, 2026. The analyst cited a 40.00 percent valuation premium and pointed to execution by Giredestrant and Fenebrutinib as important conditions for future gains.

Roche stock near its yearly high

Roche's Swiss listing was last at CHF 384.60 on October 16, 2026 at 5:19 p.m. CEST, against a 52-week range of CHF 270.80 to CHF 387.00. The upper end leaves the stock 0.62 percent below its yearly high. Trading volume was 8,950 shares, compared with an average of 27,493 shares.

Sales date and valuation

Roche will publish third-quarter sales before the Swiss market opens on October 22, 2026, followed by a presentation at 2:00 p.m. CEST, according to Roche. Roche had reported first-half sales of CHF 30.364 billion, down 2.00 percent, in the first half of 2026. The company carried a market capitalization of CHF 301.3 billion and a price-to-earnings ratio of 24.69 on October 16, 2026. Its trailing dividend yield was 0.03 percent.

Comparison with peers

Roche Holding: minus 0.41 percent, P/E 24.69, market capitalization CHF 301.3 billion

Johnson & Johnson (NYSE, USD): plus 1.45 percent, P/E 38.95, market capitalization USD 619.2 billion

Eli Lilly and Company (NYSE, USD): plus 0.91 percent, P/E 42.39, market capitalization USD 1.2 trillion

What the target means for valuation

The contrast is clear in the numbers: Roche combines a 24.69 price-to-earnings ratio with a CHF 250.00 Jefferies target and a CHF 384.60 Swiss price. The upcoming October 22, 2026 sales release is the next scheduled company date for testing that assessment.

The further course of trading is shown by the continuously updated real-time quote of Roche Holding stock.